The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $702,500 firm-fixed-price contract to Genscript USA Inc. to provide gene synthesis services in support of COVID-19 testing. Under the contract, Genscript will synthesize 150 genes and conduct 150 mutagenesis and 250 express cloning projects, as well as prepare 425 plasmids. These products and services will support the testing of COVID-19 antibody therapeutics, convalescent plasma, and vaccines...
This firm fixed-price purchase order contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $3,943.72 contract is for custom gene synthesis services to support NIAID's biomedical research programs. Genscript, a for-profit organization, has a strong track record of providing specialized molecular biology products and services to...
Genscript USA Incorporated will provide gene synthesis and vector ark cloning services to the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). Under the terms of a $12,108 firm fixed price purchase order, Genscript will deliver the requested products and services between September 2023 and September 2024. As the prime contractor, Genscript will leverage its expertise...
This is a $8,073.05 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the synthesis of a specific gene, HHSN272201200153P. Genscript, which is not a small business set-aside, has received numerous previous contracts from HHS agencies like the National Institutes of Health, Centers for...
This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Genscript USA Inc., a for-profit biotechnology company, for custom gene synthesis services. The contract has a potential value of $21,275.80 and a completion date of August 19, 2020. Genscript, based in Piscataway, New Jersey, specializes in gene synthesis, gene editing, custom protein and...
This federal contract award was issued by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $20,092.74 firm fixed price contract is for custom gene synthesis services. The contract has no set-aside designation. Genscript specializes in gene synthesis, gene editing, and other molecular biology services, and has received...
This federal contract award to Genscript USA Inc. is for $182,897.61 to provide custom gene synthesis services to the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The contract is a firm fixed-price purchase order with no set-aside designation, and the services include DNA synthesis, subcloning, and plasmid preparation to support HIV research being conducted at the NIH...
The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $20,000 firm fixed price purchase order to Genscript USA Inc. to provide custom gene synthesis services. The contract will support NIH's research efforts at its Bethesda, Maryland campus through December 31, 2023. Genscript will deliver custom gene synthesis products to NIH researchers as part of the Institute's work to advance understanding of diseases...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $17,709 purchase order to Genscript USA Inc. to provide custom gene synthesis and expression services in support of its research efforts. The firm fixed price contract has a period of performance from September 18, 2023 through December 31, 2023 and will be carried out by Genscript at its facility located in Bethesda, Maryland. No major subcontractors or set aside designations were identified....
This firm fixed-price purchase order, valued at $14,607.70, was awarded by the National Institute of Child Health and Human Development (NICHD) to Genscript USA Inc. for gene synthesis and cloning services. The ultimate completion date is August 29, 2024. Genscript is a biotechnology company based in Piscataway, New Jersey that specializes in molecular biology products and services to support biomedical research and public health initiatives for various federal agencies, including the National...